Original Article
Central
Macular Thickness: A Comparative Study of Diabetics Vs Healthy
Beenish Khan, Muhammad
Muneer Quraishy, Asma Shams
Pak J Ophthalmol 2019, Vol. 35, No. 1
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations …..……………………….. Correspondence to: Beenish Khan Assistant Professor Department of Ophthalmology United Medical and Dental College, Creek General Hospital,
Korangi, Karachi Email:
beenish_aquarian@hotmail.com |
Purpose: To compare the central macular thickness amongst diabetics with
that of healthy population by using Optical Coherence Tomography. Study Design: Case control study. Place and Duration of Study: Department
of Ophthalmology Unit I, Civil Hospital Karachi from 5th March
2012 to 4th September 2012. Material and Methods: We randomly selected patients
with diabetes (cases) and healthy patients (control) with clinically normal
macula and no diabetic retinopathy. Detailed relevant history was acquired.
Best corrected visual acuity (BCVA) was measured with standard Snellen’s
chart. Detailed dilated fundus examination was done using +90D and +78D lens. Central macular thickness within an
area of 1000 µm was measured using Optical
Coherence Tomography. Results: There were 68 patients in each group. The mean age of patients
in the Diabetic group was 47.94 ± 14 (20-80) years and in the healthy group it
was found to be 39.53 ± 14.93 (20-80) years. Out of these 26 were male and 42
were female in the diabetic group whereas 27 were male and 41 were female in
the healthy group. Mean central macular thickness of Diabetic eyes were
214.48 ± 31.41 µm and that of healthy eyes were 236.79 ± 19.38 µm with mean
difference of 22.31 ± 4 µm (p value = 0.000).. A statistically significant difference in the central
macular thickness of Diabetics and healthy patients was observed. Conclusion: The central macular thickness
is significantly decreased in eyes of patients with Diabetes. Keywords: Central macular thickness,
Optical Coherence Tomography, OCT, Diabetic Retinopathy, Diabetic
Maculopathy. |
Conventional methods of evaluating macular thickness like slit
lamp biomicroscopy and stereo fundus photography are relatively insensitive to
small changes in retinal thickness. Thus for measuring retinal thickness quantitatively
several new techniques have been explored2. Retinal imaging
techniques can provide detailed cross sectional information which can be
complementary to conventional fundus photography and fluorescein angiography3.
Optical coherence tomopgraphy (OCT) is a new medical diagnostic
imaging technology which can perform cross sectional or tomographic imaging of
biological tissues in micrometer resolution4. Its application has
been demonstrated in normal human eyes with certain macular abnormalities and
glaucoma3,5,6.
Despite normal findings in slit lamp
biomicroscopy early changes in the retinal thickness can be detected by optical
coherence tomography7 and it has been observed that a greater than
10% change in baseline macular thickness by optical coherence tomography is
considered significant8. Macular thickness measurements may be used
to assess disease, monitor its progress and evaluate treatment9.
Macular thickness has been shown to be increased in diabetics with clinically
normal macula10.
The Macular thickness measurement may
differ with the population. Thus it is desirable that measurements derived from
the normative population be as close as possible to the population for which
the instrument is to be used11.
It has been observed that strict diabetes
control slowed down the appearance of diabetic retinopathy and can play an
important part in protection of macula12-13.
The rationale of our
study is to ascertain whether there is any difference in the macular thickness
of normal with diabetics with clinically normal maculae in Pakistani
population, so that early diagnosis can be made. This will ensure that strong
check on the diabetes control is maintained and proper treatment can be applied
at proper time before the appearance of sight threatening complications.
MATERIAL AND METHODS
We randomly selected patients with
diabetes (cases) and healthy patients (control) with clinically normal macula
and no diabetic retinopathy attending the Ophthalmology out patients department
of Unit I, Civil Hospital Karachi from 5th March 2012 to
4th September 2012.
Healthy patients included in the study had
a best corrected Visual acuity of 6/6, no associated ocular co morbidity, no
history of previous ocular surgery or laser therapy, no history of systemic
disorder that can effect eye and no history or evidence of pathology features
of retina.
Diabetic patients included in the study had
established diabetes and were using insulin or oral hypoglycemic agents either
controlled or uncontrolled as detected by HbA1c. The duration of diabetes was
more than 5 years. There were no signs of diabetic maculopathy clinically.
The null hypothesis made
was made that there is no difference in macular thickness between diabetics
with clinically normal macula and healthy individuals. It was a case control
study with a sample size of 136 eyes in each
group. Sampling technique used was non probability purposive sampling.
All subjects who
fulfilled the criteria of Healthy and Diabetic subjects, subjects of either
gender, subjects ranging from 20 yrs – 80 yrs age and duration of diabetes
greater than 5 yrs were included in the study.
Patients having proliferative diabetic
retinopathy or advance diabetic eye disease, ocular comorbidities other than
diabetic retinopathy like ARMD, retinal dystrophy, glaucoma etc., history of
previous ocular surgery or laser therapy and subjects
in whom scans with signal strength ≤ 60 could not obtained on OCT were excluded from the study.
Subjects
selected from the outpatient department of civil hospital Karachi underwent
slit lamp examination including +90D and +78D lens examination after dilatation
with 1% tropicamide. We included 136 healthy eyes that fulfilled the selection
criteria. There were 136 diabetic eyes with established diabetes, using insulin
or oral hypoglycaemic agents since ≥ 5yrs that were selected. An informed
consent was taken after explaining the whole procedure. Refraction and Fundus
flourescein angiography of all patients was done to control effect modifying. All included subjects underwent scanning with a Spectral Domain
Optical Coherence tomography (SD OCT) device (3D OCT 1000 Topcon Japan) by one
designated experienced person. Follow up of the
Table 1: Base Line Characteristics.
Controls (Healthy) |
Cases (Diabetics) |
P value |
||
No. of Eyes |
136 |
136 |
|
|
Age (years) |
47.94 ± 14.07 |
39.52 ± 14.93 |
0.47* |
|
Gender No. (%) |
Males |
27 (39.7%) |
26 (38.2%) |
0.86** |
Females |
41 (60.3%) |
42 (61.8%) |
||
Mean CMT (µm) |
236.79 ± 19.38 |
214.48 ± 31.41 |
0.00* |
*Independent Sample T Test **Chi
Square Test
patient was not required.
For quantitative evaluation, the thickness of the central
circular area of 1000 micrometers in diameter was used as defined by the early
treatment diabetic retinopathy study (ETDRS).14 Statistical Packages
for Social Science (SPSS-16) was used to analyze data. Mean was calculated for
quantitative variables (central macular thickness
and age). Frequency and percentage was used
for qualitative variables like gender. Independent sample t test was used to
see the difference between the two groups i.e. diabetic and healthy. P ≤
0.05 was considered significant.
We stratified the data in multiple groups
according to age, gender, diabetic control, and duration of diabetes. Then we
calculated through chi square for both groups to see the effect of each
variable accordingly.
Age stratification was done decade wise and
7 groups were made. Group 1; 20-29 years, group 2; 30-39 years, group 3; 40-49
years, group 4; 50-59 years, group 5; 60-69 years, group 6; 70-79 years and
group 7; 80 years.
Patients were stratified in 2 groups
according to glycemic control. Group 1; controlled diabetes, group 2;
uncontrolled diabetes.
Patients were stratified
according to duration of diabetes in 5 groups. Group 1; 5-10 years, Group 2;
11-15 years, Group 3; 16-20 years, Group 4; 21-25 years.
RESULTS
There were 68 subjects in each group. Table
1 details the characteristics of both the groups. Statistically significant
difference was found with respect to age in healthy group (p = 0.038) (Table 3)
but not in diabetic group (p = 0.669) (Table 2). The two groups had
statistically insignificant variations with respect to gender (p = 0.86) (Table
1 & 4), duration of diabetes
(p = 0.311) (Table 6) and type of Diabetes (p = 0.72) (Table 5). All patients
had controlled diabetes.
The mean central macular
thickness in the control group was 236.79 ± 19.38 µm which was
Table 2: Effect of Age on CMT in Diabetic patients.
Age of the Patients in Groups |
No. of Cases |
Mean CMT |
P value |
20
– 29 yrs |
11 |
206.27±28.69 |
0.669* |
30
– 39 yrs |
3 |
217.67±50.52 |
|
40
– 49 yrs |
14 |
219.14±28.09 |
|
50
– 59 yrs |
28 |
210.93±34.94 |
|
60
– 69 yrs |
8 |
218.62±29.07 |
|
70
– 79 yrs |
4 |
235.00±11.43 |
|
Total |
68 |
|
*One
Way Anova
Table 3: Effect of Age on CMT in Healthy
subjects.
Age of the Patients in Groups |
No. of Cases |
Mean CMT |
P value |
20 – 29 yrs |
19 |
240.62 ± 20.27 |
0.038* |
30 – 39 yrs |
18 |
224.83 ± 18.78 |
|
40 – 49 yrs |
15 |
240.40 ± 16.55 |
|
50 – 59 yrs |
8 |
251.50 ± 10.85 |
|
60 – 69 yrs |
5 |
234.80 ± 23.91 |
|
70 – 79 yrs |
1 |
N/A |
|
80 yrs |
2 |
232.50 ± 3.53 |
|
Total |
68 |
|
*One
Way Anova
Table 4: Effect of Gender on CMT.
|
Gender |
P value* |
|
Male |
Female |
||
CMT Control |
245.59 ± 15.25 |
231.00 ± 19.77 |
0.086 |
CMT Case |
214.19 ± 34.69 |
214.67 ± 29.64 |
0.027 |
*Independent
Samples T test.
Table 5: Effect of Type of Diabetes on
CMT.
Type of Diabetes |
Total no of Cases |
Mean CMT |
P value* |
IDDM |
13 |
211.69 ± 27.92 |
0.72 |
NIDDM |
55 |
215.15 ± 32.38 |
*Independent
Sample T Test
Table 6: Effect of Duration of Diabetes
on CMT.
Duration of Diabetes |
No. of cases |
Mean CMT |
P value* |
5-10 yrs |
37 |
221.13
± 33.16 |
0.189 |
11-15 yrs |
19 |
206.84
± 25.26 |
|
16-20 yrs |
8 |
213.50
± 27.29 |
|
21-25 yrs |
4 |
214.48
± 40.46 |
|
Total num of cases |
68 |
|
*One
Way Anova test
significantly thicker
than the value of 214.48 ± 31.41 µm obtained for the case group (p = 0.00). The
mean central macular thickness in the cases group was thinner by 22.31 ± 4.47
µm as compared to the control group (p = 0.00). Thus the decreased CMT in
Diabetic group showed a significantly thinner mean CMT even in the absence of
clinical maculopathy.
DISCUSSION
Optical Coherence Tomography is considered
as a useful tool for the measurement of retinal thickness. It raises the
probability of correct diagnosis, helps in following the disease progression as
well as monitoring the efficacy of treatment given for diabetic retinopathy15.
That is the reason we have chosen diabetic patients with normal maculae so that
we find earliest changes that are not evident in other ways.
We included 68 diabetic cases with no
maculopathy and compared them with that of normal. The mean age of diabetic
patients was 39.52 ± 14.93 years and that of healthy group was 47.94 ± 14.07
years.
Our study showed that the mean central
macular thickness of the diabetic patients came out to be 214.48 ± 31.41 which
is thinner than the mean central macular thickness of the healthy cases 236.79 ±
19.38 µm (p 0.000). In 2013, a same study was done in Turkey also revealing
decreased macular thickness in diabetics (227.19 ± 29.94 µm in healthy as
compare to 232.12 ± 24.41 µm in diabetics)16. Murugesan S17,
and Jiang jing et al18 also found decreased central macular
thickness in clinically normal diabetic maculae in comparison to that of
healthy individuals. Statistically significant pericentral retinal thinning has
also been demonstrated by Biallosterski and co-workers19, when they
compared the retinal thicknesses of diabetics and healthy individuals,
supporting the hypothesis of nerve tissue cell loss in the initial stages of
diabetic retinopathy. In addition to this study by Nilsson et al20 also
upholds our study result by demonstrating decreased retinal thickness in
diabetic patients with early or no diabetic retinopathy.
Pre-clinical retinal nerve fiber layer
thickness is also found to be less in the superior quadrant and other areas of
retina in diabetic patients in comparison to the healthy retina21. All
of these studies suggest damage to the neural tissue in diabetes which involves
mostly the ganglion cell layer and inner plexiform layer22.
Certain factors were observed in healthy eyes
also that can directly or indirectly impact the measured central macular
thickness on OCT. These include ethnicity and gender of the subject23-24.
In our study we didn’t find any significant difference in central macular
thickness with respect to gender. Eriksson and Alm25 reported
negative relationship between retinal thickness and age for all ETDRS areas,
total macular volume and RNFL thickness in healthy individuals (Retinal
thickness decreased by 0.26-0.46 mm, macula volume 0.01 mm3 and RNFL 0.09 mm per
year). In our study significant difference was found in CMT with respect to age
in healthy groups but no definite pattern was found. There was no significant
difference in the macular thickness of diabetic group according to the age.
Overall, we found the following
findings: significant decreased central macular thickness of diabetics vs.
healthy in normal maculae, no specific pattern of macular thickness was found
according to the age, no specific pattern of macular thickness was found
according to duration of diabetes. One limitation to our article was decreased
sample size which was total of 136 eyes in both groups
CONCLUSION
Since p-value is
significant (0.000) therefore null hypothesis is rejected and we come to the
conclusion that the macular thickness of diabetic patients is less than that of
healthy individual even when there is no clinical evidence of any changes. This
study suggests that there are certain changes that occur during the course of
diabetes which lead to the retinal damage and resultant decreased thickening.
Author’s Affiliation
Dr. Beenish Khan
Assistant Professor
Department of Ophthalmology
United Medical and Dental College
Creek General Hospital
Korangi, Karachi
Dr. Muhammad Muneer Quraishy
Professor of Ophthalmology
Dow University of Health Sciences
Civil Hospital Karachi
Dr. Asma Shams
Senior Registrar Ophthalmology
Shaheed Mohtarrma Benazir Bhutto Medical College Liari
Author’s contribution
Dr. Beenish Khan
Manuscript writing, data collection, analysis and interpretation.
Dr. Muhammad MuneerQuraishy
Study concept and design.
Dr. Asma Shams
Manuscript review.
REFERENCES
1.
Klein R, Klein BE, Moss SE, Davis MD, De Mets DL. The Wisconsin
epidemiologic study of diabetic retinopathy IV. Diabetic macular edema. Ophthalmol. 1984; 91: 1464-74.
2.
Nussenblat RB, Kaufman SC, Palestine AG, Davis MD, Ferris FL. Macular thickening and visual acuity. Ophthalmology 1987; 94: 1134-9.
3.
Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JF, Wilkins JR et
al. Topography of diabetic macular
edema with optical coherence tomography. Ophthalmol.
1998; 105: 360-70.
4.
Chauhan DS, Marshall J. The interpretation of optical coherence tomography images of the
retina. Invest Ophthalmol Vis Sci. 1999;
40: 2332-42.
5.
Koozekanani D, Roberts C, Katz SE, Herderick ED. Intersession repeatability of macular thickness measurements with
the Humphrey 2000 OCT. Invest
Ophthalmol Vis Sci. 2000; 41: 1486–91.
6.
Munuera JM, Garcia-Layana A, Maldonado MJ, Aliseda D, Moreno-
Montanes J. Optical coherence
tomography in successful surgery of vitreo-macular traction syndrome. Arch Ophthalmol. 1998; 116: 1388-9.
7.
Tocino HS, Vidal AA, Maldonado MJ, Montanes JM, Layana AG. Retinal thickness study with optical coherence tomography in
patients with diabetes. Invest Ophthalmol Visual Sci.
2002; 43: 1588-94.
8.
Browning
DJ, Fraser CM, Propst BW. The
variation in optical coherence tomography–measured macular thickness in
diabetic eyes without clinical macular edema. Am J Ophthalmol. May 2008; 145 (5):
889-93.
9.
Workman HL, Hosking SL. Repeatability and reproducibility of macular thickness
measurements using OCT 3 system in normal subjects and diabetics patients.
Invest Ophthalmol Visual Sci. 2004; 45: 2378-B13.
10.
Emerah SH, Labib HM, Farag MY, Kamel HF. Macular thickness measurements in diabetic patients without
diabetic retinopathy using optical coherence tomography. J Am Sci. 2011; 7 (11):
223-7.
11.
Tewari HK, Wagh VB, Sony P, Venkatesh P, Singh R. Macular thickness evaluation using the optical coherence
tomography in normal Indian eyes. Ind J Ophthalmol. 2004; 52 (3): 199-204.
12.
Peng YJ, Tsai MJ.
Impact of metabolic control on macular thickness in diabetic macular oedema. Diab
Vasc Dis Res. 2018; 15 (2): 165-8.
13.
Teberik K, Eski MT, Kaya M. Associations of glycated hemoglobin (HbA1c) level with central
corneal and macular thickness in diabetic patients without macular edema, 2018;
4 (4): 294-9.
14.
Early
treatment diabetic retinopathy study research group. Photocoagulation for
diabetic macular edema. ETDRS report number 1. Arch Ophthalmol. 1985; 103: 1796-806.
15.
Hannouche
RZ, Avila MP. Retinal thickness measurement
and evaluation of natural history of the diabetic macular edema through optical
coherence tomography. Arq Bras Oftalmol. 2009; 72 (4): 433-8.
16.
Demir M, Dirim B, Acar Z, Yilmaz M and Sendul Y. Central Macular Thickness in Patients with Type 2 Diabetes Mellitus
without Clinical Retinopathy. J Ophthalmol, 2013.
17.
Murugesan S, Jha K N, Krishnagopal S and Ezhumalai G. Central macular thickness in diabetics without retinopathy. TNAO
J Ophthalmic Sci & Research, 2018; 56 (3): 150-4.
18.
Jiang J, Liu Y, Chen Y, Ma B, Qian Y, Zhang Z et al. Analysis of Changes in Retinal Thickness in Type 2 Diabetes
without Diabetic Retinopathy. J Diabetes Research, 2018.
19.
Biallosterski
C, van Velthoven ME, Michels RP et al.
Decreased optical coherence
tomography-measured pericentral retinal thickness in patients with diabetes
mellitus type 1 with minimal diabetic retinopathy. Br J Ophthalmol. 2007; 91 (9):
1135-8.
20.
Nilsson
M, Wendt G, Wanger P, Martin L.
Early detection of macular changes in patients with diabetes using Rarebit
Fovea Test and optical coherence tomography. Br J Ophthalmol. 2007; 91 (12): 1596-8.
21.
Peng
HP, Lin HS, Lin S. Nerve
fibre layer thinning in patients with preclinical retinopathy. Can J
Ophthalmol. 2009; 44 (4): 417-22.
22.
Cabrera
BD, Somfai GM. Early detection of retinal
thickness changes in diabetes using Optical Coherence Tomography. Med Sci Monit.
2010; 16 (3): 15-21.
23.
Kelty
PJ, Payne JF, Trivedi RH, Kelty J, Bowie EM, Burger BM. Macular thickness assessment in healthy eyes based on ethnicity
using stratus optical coherence tomography. Invest Ophthalmol Visual Sci. 2008;
49: 2668-72.
24.
Ooto
S, Hangai M, Sakamoto A, Tomidokoro A, Araie M, Otani T, et al. Three-dimensional profile of macular retinal thickness in normal Japanese
eyes. Invest Ophthalmol Visual Sci.
2010; 51: 465-73.
25.
Eriksson U, Alm A.
Macular thickness decreases with age in normal eyes: a study on the macular
thickness map protocol in the Stratus OCT. Br J Ophthalmol. 2009; 93: 1448-52.